Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction

Diabetes, Obesity and Metabolism

Volumn 13, Issue 1, 2011, Pages 75-80

  Morrow, L ^a   Hompesch, M ^a   Guthrie, H ^a   Chang, D ^b   Chatterjee, D J ^b  

^a Profil Institute for Clinical Research Inc   (United States)

^b NOVO NORDISK INC   (United States)

Author keywords

Combination therapy; GLP 1 analogue; Insulin detemir; Liraglutide; Pharmacodynamics; Pharmacokinetics

Indexed keywords

HEMOGLOBIN A1C; INSULIN DETEMIR; LIRAGLUTIDE; METFORMIN; ORAL ANTIDIABETIC AGENT;

ABDOMINAL DISCOMFORT; ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG SAFETY; FEMALE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PHARMACODYNAMICS; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; WEIGHT REDUCTION;

EID: 78649694786     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01322.x     Document Type: Article

References (23)

1. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care 2008; 31: 81-86.
2. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-2012.
3. Rodbard HW, Jellinger PS, Davidson JA et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009; 15: 540-559.
4. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002; 287: 360-372.
5. Buse JB, Rosenstock J, Sesti G et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39-47.
6. Garber A, Henry R, Ratner R et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473-481.
7. Marre M, Shaw J, Brandle M et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26: 268-278.
8. Nauck MA, Frid A, Hermansen K et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met). Diabetes Care 2009; 32: 84-90.
9. Pratley R, Nauck M, Bailey T et al. Liraglutide treatment for 1 year offers sustained and more effective glycemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes [abstract]. Presented at 70th American Diabetes Association Scientific Sessions, Orlando, FL, 5-9 June 2010. Available from URL: Accessed 4 August 2010.
10. Russell-Jones D, Vaag A, Schmitz O et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomized controlled trial. Diabetologia 2009; 52: 2046-2055.
11. Zinman B, Gerich J, Buse J et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care 2009; 32: 1224-1230.
12. Victoza® [package insert]. Novo Nordisk, Inc. Princeton, NJ, January 2010. Available from URL: Accessed 4 August 2010.
13. Levemir [package insert]. Novo Nordisk, Inc. Princeton, NJ, 2009. Available from URL: Accessed 4 August 2010.
14. Declaration of Helsinki. 2010. Available from URL: Accessed 4 August 2010.
15. Agersø H, Jensen LB, Elbrønd B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002; 45: 195-202.
16. Brunner GA, Sendhofer G, Wutte A et al. Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans. Exp Clin Endocrinol Diabetes 2000; 108: 100-105.
17. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes. Diabetes Care 2005; 28: 1245-1249.
18. Kolendorf K, Ross GP, Pavlic-renar I et al. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in type 1 diabetes. Diabet Med 2006; 23: 729-735.
19. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide-the FDA's review of a new antidiabetic therapy. N Engl J Med 2010; 362: 774-777.
20. Agerso H, Jensen LB, Elbrond B, Rolan B, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002; 45: 195-202.
21. Plank J, Bodenlenz M, Sinner F et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005; 28: 1107-1112.
22. Havelund S, Plum A, Ribel U et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 2004; 21: 1498-1504.
23. Drucker DJ, Dritselis A, Kirkpatrick P. Liraglutide. Nat Rev Drug Discov 2010; 9: 267-268.